<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03863938</url>
  </required_header>
  <id_info>
    <org_study_id>CJ_APA_112</org_study_id>
    <nct_id>NCT03863938</nct_id>
  </id_info>
  <brief_title>Food-Effect on PK and PD of Single Oral Dose of Tegoprazan in Healthy Male Subjects</brief_title>
  <official_title>A Randomized, Open-label, Single-dose Phase 1 Clinical Trial to Compare the Effect of Timing of Food on the Pharmacokinetics and Pharmacodynamics of K-CAB (Tegoprazan) in Healthy Male Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>HK inno.N Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>HK inno.N Corporation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to evaluate the food-effect of tegoprazan 50mg on the pharmacokinetics and
      pharmacodynamics in healthy H. pylori negative male volunteers
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Primary Outcome Measure:

        1. AUClast and Cmax of tegaprazan

        2. Gastric pH
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 27, 2019</start_date>
  <completion_date type="Actual">June 25, 2019</completion_date>
  <primary_completion_date type="Actual">April 26, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>AUClast of tegaprazan</measure>
    <time_frame>Pre-dose(0 hour) and up to 48 hours in each period</time_frame>
    <description>Area under the plasma concentration versus time curve of tegoprazan</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax of tegaprazan</measure>
    <time_frame>Pre-dose(0 hour) and up to 48 hours in each period</time_frame>
    <description>Peak Plasma Concentration of tegoprazan</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Gastric pH</measure>
    <time_frame>Pre-dose(0 hour) up to 24 hours after Investigational product administration in each period</time_frame>
    <description>Gastric pH</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Tegoprazan 50mg under fasting condition</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment A: single oral administration of Tegoprazan 50mg tablet under fasting condition once a day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Tegoprazan 50mg before the meal</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment B: single oral administration of Tegoprazan 50mg tablet before the meal once a day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Tegoprazan 50mg after the meal</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment C: single oral administration of Tegoprazan 50mg tablet after the meal once a day</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tegoprazan 50mg</intervention_name>
    <description>K-CAB</description>
    <arm_group_label>Tegoprazan 50mg after the meal</arm_group_label>
    <arm_group_label>Tegoprazan 50mg before the meal</arm_group_label>
    <arm_group_label>Tegoprazan 50mg under fasting condition</arm_group_label>
    <other_name>Tegoprazan 50mg tablet</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy adult males aged ≥ 19 years and ≤ 50 years

          -  Body weight of ≥ 55.0 kg and ≤ 90.0 kg, with body mass index (BMI) of ≥ 18.0 kg/m2 and
             ≤ 27.0 kg/m2 at the time of screening

          -  Helicobacter pylori negative

        Exclusion Criteria:

          -  Presence or history of clinically significant diseases

          -  Presence or history of gastrointestinal disorder (gastric ulcer, GERD, Crohn's
             disease, etc.)

          -  Hypersensitivity to drugs containing study drug or proton pump inhibitor and other
             drugs (aspirin, antibiotics, etc.) or history of clinically significant
             hypersensitivity

          -  Serologic test positive

          -  Abnormal obstacle to insertion and maintenance of pH meter catheter

          -  History of drug abuse

          -  Excessive caffeine intake or persistent alcohol intake

          -  Not use of a medically acceptable method of contraception
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>In-Jin Jang, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Seoul National University Hospital, Dept. of Clinical Pharmacology</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Seoul National University Hospital, Clinical Trial Center</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>February 28, 2019</study_first_submitted>
  <study_first_submitted_qc>March 3, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 5, 2019</study_first_posted>
  <last_update_submitted>August 20, 2019</last_update_submitted>
  <last_update_submitted_qc>August 20, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 22, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

